Laboratorios Farmaceuticos Rovi revenue and financials
€59.10Change from previous close: +1.63%Absolute change: +€0.95
In the fiscal year ended December 2025, Laboratorios Farmaceuticos Rovi reported revenue of €743.48M (−2.65% year over year). Net income was €140.44M, a net margin of 18.9%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- −2.65%
- 2025 vs 2024
- Net income growth
- +2.60%
- 2025 vs 2024
- Net margin
- 18.9%
- 2024: 17.9%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | 187 | 138 | 113 | 238 | — |
| Depreciation and amortization | 30.4 | 28.0 | 24.3 | 22.9 | — |
| Capital expenditure | -67.8 | -62.2 | -55.2 | -51.4 | — |
| Investing cash flow | -68.5 | -81.1 | -52.0 | -57.2 | — |
| Financing cash flow | -47.8 | -55.4 | -161 | -155 | — |
| Dividends paid | -47.8 | -56.5 | -69.0 | -51.0 | — |
| Share repurchases | -54.9 | -89.7 | -134 | -177 | — |
| Debt issued | 47.6 | 97.0 | 0.7 | 1.4 | — |
| Debt repaid | -46.8 | -51.7 | -13.7 | -6.8 | — |
| Net change in cash | 70.8 | 1.9 | -99.6 | 25.9 | — |
| Free cash flow | 119 | 76.1 | 58.1 | 186 | — |